Egyptian Rheumatology and Rehabilitation

Table 2 Distribution of the sociodemographic, clinical, laboratory, and imaging data among the AS group

From: Association of vascular endothelial growth factor serum levels with ankylosing spondylitis in Egyptian patients

		N		%
Smoking	No	46		65.71
Smoking	Yes	24		34.29
Comorbidity	No	58		82.86
Comorbidity	Yes	12		17.14
Disease duration (years)	Range	1	-	20
Disease duration (years)	Mean ± SD	6.029	±	4.403
Morning stiffness (hours)	Range	1	-	2
Morning stiffness (hours)	Mean ± SD	1.286	±	0.404
Peripheral arthritis	No	52		74.29
Peripheral arthritis	Yes	18		25.71
Extraarticular	No	62		88.57
Extraarticular	Yes	8		11.43
CBC	No	40		57.14
CBC	Yes	30		42.86
ESR	Range	9	-	46
ESR	Mean ± SD	27.200	±	10.794
CRP titer	Range	2	-	15
CRP titer	Mean ± SD	6.940	±	3.093
HLAB27	Negative	54		77.14
HLAB27	Positive	16		22.86
BASFI	Range	3	-	9.5
BASFI	Mean ± SD	5.637	±	1.849
ASDAS	Range	0.5	-	3.9
ASDAS	Mean ± SD	2.183	±	0.939
X-ray score	Range	1	-	3
X-ray score	Mean ± SD	1.971	±	0.701
MSASS	Range	12	-	66
MSASS	Mean ± SD	31.857	±	15.150
Treatment	Non-TNF (il17)	10		14.29
	TNF (etanercept)	40		57.14
	TNF (golimumab)	12		17.14
	TNF (adalimumab)	8		11.43
Treatment duration (months)	Range	12	-	72
Treatment duration (months)	Mean ± SD	35.257	±	14.229
Nonbiologic	NSAID	54		77.14
Nonbiologic	NSAID + sulfasalazine	16		22.86

CBC Complete blood picture, ESR Erythrocyte sedimentation rate, CRP C-reactive protein, HLA Human leucocyte antigen, BASFI Bath Ankylosing Spondylitis Functional Index, VEGF Vascular endothelial growth factor, ASDAS Ankylosing Spondylitis Disease Activity Score, MSASS Modified Stoke Ankylosing Spondylitis Spine Score, NSAID Nonsteroidal anti-inflammatory drugs, TNF Tumor necrosis factor, N Number, % percentage. SD Standard deviation

Back to article page